News: CYP Cynata Therapeutics seeks trading halt, page-94

Another big Japanese player has entered the MSC market this week:

Otsuka Pharmaceutical Co. Ltd
MC US$25.382 billion (in comparison: FujiFilm US$19.164 billion)

"Otsuka Pharmaceutical Co., Ltd. (Otsuka) and TWO CELLS Company, Limited (TWO CELLS) entered into an agreement for Otsuka to purchase new shares issued by TWO CELLS. At the same time, the two companies will promote efforts to collaborate further in regenerative cell therapies based on Mesenchymal Stem Cells (MSCs) for the treatment of central nervous system disorders.*

Otsuka and TWO CELLS together will accelerate efforts to develop practical applications of MSC-derived regenerative therapies."

http://www.otsuka.co.jp/en/company/release/detail.php?id=3270

As we know, there is only ONE technology that can offer

• Unlimited Quantities
• Uniform Batches
• Single Donor
• Economic Manufacture at Commercial Scale

(source: https://www.bioinformant.com/cynatas-cymerus-platform-technology-what-is-it-exactly/)